Hot Topics of Medical Affairs
COVID-19 Vaccine – May 5th, 2020 at 6:45 AM EDT, Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
The following article was originally posted on the Faculty of Pharmaceutical Medicine’s website. It is reposted here with their express permission. This article has been prepared by Dr. Penny Ward FFPM, with input from Professor Tim Higenbottam PFPM, Dr. Flic Gabbay FFPM, Dr. Bob Holland FFPM, Dr. Sue Tansey FFPM, and Dr. Tahir Saleem MFPM. […]
We know that Medical Affairs and Medicines Development Professionals around the world have been working non-stop to develop vaccines, treatments, testing, and medical devices in response to the COVID-19 pandemic. To aide in the distribution of information, we have provided below important clinical trial guidance from different sources for use during this pandemic.
Each year, The FPM (Faculty of Pharmaceutical Medicine) Fellows are invited to nominate exceptional individuals for Honorary Fellowship. According to the FPM’s website, Honorary Fellowship is the highest honor FPM can bestow, it recognizes the recipient’s eminence within their own field and their outstanding contribution to pharmaceutical medicine. On the recommendation of the Fellowship and […]
A study that will provide much-needed insight for healthcare providers and pharmaceutical companies, allowing for a truly patient-centric approach with precision medicine. “The ultimate goal of the All of Us Research Program is to collect information to lead to incredible discoveries in biomedical research and precision medicine, but along the way, we are going to transform lives. […]